Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model

Yumiko Okano Tamura, Jun Sugama, Shinji Iwasaki, Masako Sasaki, Hironobu Yasuno, Kazunobu Aoyama, Masanori Watanabe, Derek M. Erion, and Hiroaki Yashiro

Cardiovascular and Metabolic Drug Discovery Unit (Y.O.T., J.S., M.W.), Drug Metabolism & Pharmacokinetics Research Laboratories (S.I., K.A.), Biomolecular Research Laboratories (M.S.), and Drug Safety Research Laboratories (H.Yasu.), Takeda Pharmaceutical Company Limited, Kanagawa, Japan; and Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts (D.M.E., H.Yash.)

Received June 7, 2021; accepted September 14, 2021

ABSTRACT

Acetyl-CoA carboxylase (ACC) 1 and ACC2 are essential rate-limiting enzymes that synthesize malonyl-CoA (M-CoA) from acetyl-CoA. ACC1 is predominantly expressed in lipogenic tissues and regulates the de novo lipogenesis flux. It is upregulated in the liver of patients with nonalcoholic fatty liver disease (NAFLD), which ultimately leads to the formation of fatty liver. Therefore, selective ACC1 inhibitors may prevent the pathophysiology of NAFLD and nonalcoholic steatohepatitis (NASH) by reducing hepatic fat, inflammation, and fibrosis. Many studies have suggested ACC1/2 dual inhibitors for treating NAFLD/NASH; however, reports on selective ACC1 inhibitors are lacking. In this study, we investigated the effects of compound-1, a selective ACC1 inhibitor for treating NAFLD/NASH, using preclinical in vitro and in vivo models. Compound-1 reduced M-CoA content and inhibited the incorporation of [14C] acetate into fatty acids in HepG2 cells. Additionally, it decreased hepatic M-CoA content and inhibited de novo lipogenesis in C57BL/6J mice after a single dose. Furthermore, compound-1 treatment of 8 weeks in Western diet-fed melanocortin 4 receptor knockout mice—NAFLD/NASH mouse model—improved liver hypertrophy and reduced hepatic triglyceride content. The reduction of hepatic M-CoA by the selective ACC1 inhibitor was highly correlated with the reduction in hepatic steatosis and fibrosis. These findings support further investigations of the use of this ACC1 inhibitor as a new treatment of NAFLD/NASH.

SIGNIFICANCE STATEMENT

This is the first study to demonstrate that a novel selective inhibitor of acetyl-CoA carboxylase (ACC) 1 has anti–nonalcoholic fatty liver disease (NAFLD) and anti–nonalcoholic steatohepatitis (NASH) effects in preclinical models. Treatment with this compound significantly improved hepatic steatosis and fibrosis in a mouse model. These findings support the use of this ACC1 inhibitor as a new treatment for NAFLD/NASH.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by excessive fat accumulation in hepatocytes that is not caused by alcohol consumption (Vernon et al., 2011; Friedman et al., 2018). Nonalcoholic steatohepatitis (NASH) is a subcategory of NAFLD and is defined on the basis of the following liver biopsy histologic features: lobular inflammation, hepatocellular ballooning, fibrosis, and steatosis (Williams et al., 2011; Siddiqui et al., 2018). Since NAFLD and NASH are associated with cirrhosis and hepatocellular carcinoma (Ansee et al., 2013), they also represent important factors that contribute to the recent increase in liver-related morbidity and mortality.

The global prevalence of NAFLD has continued to increase annually with 25% of the world population affected in 2018 (Younossi et al., 2019). Although up to 30% of patients with NAFLD develop NASH (Calzadilla Bertot and Adams, 2016), no anti-NAFLD/anti-NASH drugs have been approved (Sanyal et al., 2010; Cusi et al., 2016; Esler and Bence, 2019), thus resulting in an unmet medical need. Hepatic steatosis is caused by an imbalance in hepatic lipid metabolism favoring the storage of lipids within the liver (Cohen et al., 2011), which triggers hepatic inflammation and, subsequently, fibrosis,
which drives NASH progression. Furthermore, metabolic syndromes, such as obesity, insulin resistance, and dyslipidemia, represent the major risk factors for the development of NAFLD/NASH. Therefore, multiple clinical trials are focusing on correcting the dysfunctional lipid metabolism via the application of lipid metabolism pathway modulators, nuclear hormone receptor agonists, and glycemic modulators (Esler and Bence, 2019).

Acetyl-CoA carboxylase (ACC) is an essential rate-limiting enzyme in fatty acid metabolism that catalyzes the carboxylation of acetyl-CoA to form malonyl-CoA (M-CoA) (Brownsey et al., 1997). Mammals have two ACC isoforms. ACC1 is localized in the cytosol and predominantly expressed in lipogenic tissues, such as the liver and adipose tissue, whereas ACC2 is localized in the mitochondrial surface and is predominantly expressed in oxidative tissues, including skeletal muscle and heart, and to some extent in the liver and adipose tissues (Abu-Elheiga et al., 2001). M-CoA produced by ACC1 is an intermediate in de novo lipogenesis (DNL) and acts as a substrate for fatty acid synthase in acyl-chain elongation (Mao et al., 2006). Furthermore, M-CoA produced by ACC2 inhibits carnitine palmitoyltransferase 1, which participates in regulating fatty acid β-oxidation (Abu-Elheiga et al., 2001, 2003).

Indeed, several studies have shown that liver-specific ACC1 knockout (KO) mice have reduced hepatic DNL, M-CoA, and triglyceride (TG) accumulation (Mao et al., 2006; Harada et al., 2007), whereas ACC2 KO mice exhibit increased fatty acid oxidation coupled with elevated whole-body energy expenditure and improved whole-body adiposity compared with wild-type mice (Abu-Elheiga et al., 2001; Choi et al., 2007).

Recently, several ACC1/2 dual inhibitors have been investigated for treating NAFLD/NASH in preclinical and clinical studies (Chen et al., 2019; Esler and Bence, 2019), many of which have reported that these dual inhibitors induce undesirable effects, including plasma TG elevation, which may be caused by excessive suppression of ACC activity. However, the anti-NAFLD/anti-NASH effect of selective ACC1 inhibitors has not been evaluated in preclinical or clinical studies to understand whether the therapeutic window for ACC1 inhibitors would be greater than that for ACC1/2 inhibitors.

To support the efficacy of ACC1 inhibitor, selective ACC1 suppression using antisense oligonucleotides demonstrated both reduced triglyceride synthesis and increased fat oxidation in primary rat hepatocytes (Savage et al., 2006). Furthermore, hepatic DNL is markedly higher in patients with NAFLD than in healthy subjects (Donnelly et al., 2005; Fabbriini et al., 2008; Lambert et al., 2014). Lastly, ACC1 but not ACC2 expression has been reported as upregulated in the liver of patients with NAFLD (Kohjima et al., 2007). These data suggest that ACC1 inhibition alone could have the potential to improve hepatic steatosis and fibrosis.

Recently, Mizojiri et al. (2018) generated a systemic selective human ACC1 inhibitor, compound-1 (selectivity >17,000-fold over that for human ACC2). To investigate the anti-NAFLD/anti-NASH effect of ACC1 inhibition, we evaluated the effect of compound-1 on M-CoA production and hepatic DNL in vitro and in vivo. Additionally, we investigated the effects of compound-1 on hepatic steatosis and fibrosis by using Western diet (WD)-fed melanocortin 4 receptor (MC4R) KO mice, a genetic and obesogenic dietary model that mimics the human pathophysiology of NAFLD/NASH with obesity, insulin resistance, excessive lipid accumulation, and enhanced liver fibrosis (Itoh et al., 2011; Konuma et al., 2015; Shiba et al., 2018). Taken together, these data are supportive of the critical role of ACC1 in the pathophysiology of liver diseases.

**Materials and Methods**

**Compounds.** Compounds used in the study were synthesized by Takeda Pharmaceutical Company Limited (Katagawa, Japan). In the animal studies, compounds were suspended in 0.5% methylcellulose (MC).

**Mouse and Human ACC Enzyme Assays.** Compounds were dissolved in DMSO and then diluted with an enzyme reaction buffer [50 mM HEPES (pH 7.5), 10 mM MgCl2, 10 mM tripotassium citrate, 2 mM dithiothreitol, and 0.001% fatty acid–free bovine serum albumin]. Recombinant mouse ACC1 or ACC2 produced by SF-9 cells was diluted with the enzyme reaction buffer to 0.8 µg/ml and 0.1 µg/ml, respectively. A 5-µl aliquot of the compound solution was added to each well of a 384-well assay plate, and 10 µl of the enzyme mixture was added to each well. The mixture was incubated at room temperature for 60 minutes. Next, a substrate solution (50 mM KHCO3, 200 µM ATP, and 5 µl of 200 µM acetyl-CoA) was added to each well, and the mixture was reacted at room temperature for 15 minutes. The reaction was stopped by adding 40 µl of stop solution (1.3% formic acid, 0.2 µM malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures. The production of M-CoA was detected using RapidFire mass spectrometry (API4000; Sciex, Tokyo, Japan) and corrected with malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures. The production of M-CoA was detected using RapidFire mass spectrometry (API4000; Sciex, Tokyo, Japan) and corrected with malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures. The production of M-CoA was detected using RapidFire mass spectrometry (API4000; Sciex, Tokyo, Japan) and corrected with malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures. The production of M-CoA was detected using RapidFire mass spectrometry (API4000; Sciex, Tokyo, Japan) and corrected with malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures. The production of M-CoA was detected using RapidFire mass spectrometry (API4000; Sciex, Tokyo, Japan) and corrected with malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures. The production of M-CoA was detected using RapidFire mass spectrometry (API4000; Sciex, Tokyo, Japan) and corrected with malonyl-13C3-CoA; 655759; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) to each of the obtained reaction mixtures.

**Measurement of M-CoA Content in HepG2 Cells.** HepG2 cells were plated in a 12-well plate at 2.4 × 105 cells/well and incubated for 48 hours under 5% CO2 at 37°C. After the medium was removed, cells were incubated in Dulbecco’s modified Eagle medium (DMEM) (10567014; Thermo Fisher Scientific, Tokyo, Japan) containing 10% fetal bovine serum (SH30084.03; Hyclone Laboratories Inc., Logan, UT), penicillin, and streptomycin under 5% CO2 at 37°C.

**Measurement of DNL in HepG2 Cells.** HepG2 cells were plated in a 24-well plate at 1.5 × 104 cells/well and incubated for 24 hours under 5% CO2 at 37°C. The cells were washed twice with 500 µl of ice-cold PBS, and 1200 µl of ice-cold 6% hydrogen peroxide was added to lyse the cells. After the cell lysates were collected in tubes, samples were immediately stored at −80°C until analysis. Refer to the experimental section on "Measurement of Cellular or Hepatic M-CoA" for the measurements.

**Measurement of DNL in HepG2 Cells.** HepG2 cells were plated in a 24-well plate at 1.5 × 104 cells/well and incubated for 24 hours under 5% CO2 at 37°C. After the medium was removed, cells were incubated with 5% DMSO or compound-1 in the assay medium (DMEM containing 0.09% fatty acid–free bovine serum; 017-22231; Fujifilm Wako Pure Chemical Industries, Osaka, Japan) for 2 hours. Next, the cells were washed with 500 µl of ice-cold PBS, and 1200 µl of ice-cold 6% hydrogen peroxide was added to lyse the cells. After the cell lysates were collected in tubes, samples were immediately stored at −80°C until analysis. Refer to the experimental section on "Measurement of Cellular or Hepatic M-CoA" for the measurements.
a scintillation A cocktail. Radioactivity was measured using liquid scintillation counting in 3110 TR (PerkinElmer Inc., Waltham, MA).

Animals. Animal experiments were approved by the Institutional Animal Care and Use Committee of Shonan Research Center, Takeda Pharmaceutical Company Limited (Katagawa, Japan), and conformed to the guidelines of the US National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Male C57BL/6J mice were purchased from Charles River Laboratories Japan (Yokohama, Japan) and fed normal chow (CE-2; CLEA Japan, Inc., Tokyo, Japan). Male Mdr null (MC4R KO) mice were generated after a previous study (Matsumoto et al., 2020). MC4R KO mice and wild-type littermate mice were fed CE-2. All animals were housed in a group under controlled conditions including a 12-hour/12-hour light/dark cycle at 20–26 °C and humidity of 40–70%; they were allowed free access to food and tap water.

Evaluation of the Effect of a Single Dose of Compound-1 on Hepatic M-CoA in CE-2-Fed C57BL/6J Mice (Dose-Response Study). Seven-week-old CE-2-fed C57BL/6J mice were divided into eight groups of five mice each based on body weight (BW) and BW change during habituation. Mice were orally administered (10 ml/kg volume) with vehicle (0.5% MC), compound-1, or compound-2 and sacrificed after 2 hours of treatment under isoflurane anesthesia. Blood samples were collected from the abdominal vena cava and centrifuged at 13,000 × g for 5 minutes at 4 °C to collect plasma, which was stored at −80 °C for pharmacokinetic analysis. After the liver weight was measured, liver samples were immediately frozen and stored at −80 °C for M-CoA measurement and pharmacokinetic (PK) analysis. Refer to the M-CoA and PK experimental section for the measurements.

Evaluation of the Effect of a Single Dose of Compound-1 on Hepatic DNL in WD-Fed C57BL/6J Mice. Seven-week-old mice were divided into four groups of three mice each based on BW after they were fed WD (D12079B; Research Diets, Inc., New Brunswick, NJ) for 3 days. Mice were orally administered (10 ml/kg volume) vehicle (0.5% MC) or compound-1 (10 mg/kg) and intraperitoneally administered 14C-acetate (400 µCi/5 ml/kg) after 1 hour of treatment. Mice were sacrificed after 2 or 5 hours of drug treatment under isoflurane anesthesia. The radioactivity of the fatty acid fraction in the liver was measured according to a previous study (Harwood et al., 2003).

Repeated Dose Study of Compound-1 in WD-Fed MC4R KO Mice. Nine-week-old MC4R KO mice were fed WD, and wild-type (WT) mice were fed CE-2. At the age of 23 weeks, WD-fed MC4R KO mice were divided into four groups of eight mice each based on BW, food intake (FI), plasma glucose, TG, total cholesterol (TC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and insulin at day −3. Mice were orally administered (5 ml/kg volume) vehicle (0.5% MC) or compound-1 (3, 10, and 30 mg/kg) once daily for 8 weeks.

BW and FI were monitored every 3–4 days. On days 17, 31, and 56, blood samples were collected from the tail vein for the measurement of plasma parameters. Plasma glucose, TG, TC, AST, and ALT were enzymatically measured using an AutoAnalyzer 7180 (Hitachi High-Technologies Corporation, Tokyo, Japan). Plasma insulin levels were measured using sandwich ELISA (Shibayagi, Gunma, Japan, or Morinaga Institute of Biologic Science, Kanagawa, Japan).

For pharmacokinetic analysis, blood samples were collected from the tail vein at day 56. Blood samples were centrifuged at 13,000 × g for 5 minutes at 4 °C to collect plasma, which was stored at −80 °C for pharmacokinetic analysis. Refer to the PK experimental section for the measurements.

Mice were sacrificed under isoflurane anesthesia on day 0 (pre) and day 60. Blood samples were collected from the abdominal vena cava and centrifuged at 13,000 × g for 5 minutes at 4 °C to collect plasma, which was stored at −80 °C for the measurement of parameters. After the liver weight was measured, liver samples were immediately frozen in liquid nitrogen and stored at −80 °C. For histopathological analysis, liver samples were stored in 10% neutral buffered formalin.

The hepatic TG content was measured as follows. First, 900 µl of saline was added to 100 mg liver tissue and homogenized (27 Hz, 2 minutes) with zirconia beads. The homogenate (200 µl) was mixed thoroughly with 600 µl of CHCl3:MeOH (1:2) for 30 minutes. After 200 µl of CHCl3 and 200 µl of H2O were added to the mixed homogenate, it was stirred for 10–30 minutes. After centrifugation (12,000 × g, 2 minutes, room temperature), the CHCl3 layers were collected, and 50 µl was dried under N2 gas and resuspended in isopropanol (80 µl for WT mouse sample and 300 µl for MC4R KO mouse sample). Extracted triglyceride content was measured using the Triglyceride-B test (432–40201; Fujifilm Wako Pure Chemical Industries, Osaka, Japan).

The hepatic collagen levels were measured using a commercially available kit (QZBTOTCOL1; Quickzyme Biosciences, Leiden, Netherlands) according to manufacturer's instructions.

The percentage of hepatic Sirius red-positive area was measured as follows. Liver samples fixed with 10% neutral buffered formalin were embedded in paraffin. Liver histology was assayed in 4-µm-thick sections stained with H&E and Sirius red. The Sirius red-positive areas were quantified using four randomly selected fields per liver sample by using the WinROOF software (Mitani Co., Tokyo, Japan). The pathologist was blinded to the animal information until the completion of the measurement.

Hepatic mRNA levels were measured as follows. Total RNA was isolated from the liver samples that were stored in RNA later by using a Lipid Tissue Mini kit (Qiagen, Tokyo, Japan). Reverse-transcription reactions were performed using a SuperScript VILO cDNA synthesis kit (Thermo Fisher Scientific, Tokyo, Japan), according to manufacturer's instructions. Gene expression was quantified by TaqMan real-time PCR (ABI7900; Thermo Fisher Scientific, Tokyo, Japan) using Platinum qPCR SuperMix-UDG (Thermo Fisher Scientific, Tokyo, Japan) and primer/Taqman probe sets (Thermo Fisher Scientific, Tokyo, Japan). The following primer-probe sets were used: monocyte chemotactrant protein-1 (Ccl2; Mm00414242_m1), adhesion G protein-coupled receptor E1 (F4/80; Mm00802529_m1), collagen type 1 (Col1α1; Mm00816661_g1), collagen type 1 α2 (Col1α2; Mm00483588_m1), 3-smooth muscle actin (Acta2; Mm00752412_s1), transforming growth factor-β1 (Tgfβ1; Mm01198220_m1), acetyl-CoA carboxylase x (Accac; Mm01304257_m1), acetyl-CoA carboxylase β (Accb; Mm01204671_m1), fatty acid synthase (Pann; Mm006623-19_m1), stearoyl-CoA desaturase 1 (Sod1; Mm00772290_m1), and ribosomal protein lateral stalk subunit P0 (36B4, Mm00725448_s1). The relative gene expression was calculated using the ΔΔCT method and normalized to 36B4 expression.

Measurement of Cellular or Hepatic M-CoA. Tissue samples were homogenized in 6% perchloric acid containing malonyl-13C3-CoA (Sigma-Aldrich, St. Louis, MO) as an internal standard. After centrifugation, the supernatant was subjected to solid-phase extraction by using an Oasis HLB Extraction Cartridge (Waters, Milford, MA). The analyte was eluted with acetonitrile and supplemented with dibutyrammonium acetate (Tokyo Chemical Industries, Tokyo, Japan), which was followed by rinsing of the column with ultrapure water. The eluate was dried under a stream of nitrogen, and the residue was reconstituted in 100 µl of ultrapure water. An aliquot of 10 µl was injected into the liquid chromatography–tandem mass spectrometry system, which consisted of a Shimadzu LC-20AD HPLC system (Shimadzu, Kyoto, Japan) and an API5000 or API5500 mass spectrometer (AB Sciex, Foster City, CA). The analytical column was a CARCCELL CORE C18 column (2.7 µm, 2.1 × 50 mm; Shiseido, Kanagawa, Japan) used at 40°C. The mobile phases consisted of (A) 50 mM ammonium carbonate/ammonium hydroxide (pH 9) supplemented with dibutyrammonium acetate and (B) acetonitrile. The analyte was eluted using a gradient of 95% solvent A/5% solvent B to 5% solvent A/95% solvent B. The flow rate of the mobile phase was 0.3 ml/min. Detection was performed using multiple-reaction monitoring in the positive ionization mode [selected reaction monitoring m/z = 584.1 → 347.1 or 584.1 → 303.3 for M-CoA and m/z = 857.2 → 350.2 for malonyl-13C3-CoA (internal standard)]. Analyst software (version 1.6.2, AB Sciex) was used for data acquisition and processing. The concentration
of compounds in each sample was back-calculated using a calibration curve generated from a series of calibration standards.

**Statistical Analysis.** All data in the graph are represented as mean ± S.D. Statistical analyses were performed in EXSUS ver.8.0 in combination with SAS ver. 9.3 or GraphPad PRISM software. To evaluate the effects of compound-1 in vivo, we analyzed the statistical differences between vehicle and drug treatment in C57BL/6J mice or MC4R KO mice using Student’s *t* test, Aspin-Welch test, Dunnett’s test, and Steel’s test. To confirm the establishment of the disease state, we analyzed the statistical differences between WT mice and vehicle by using Student’s *t* test or Aspin-Welch test. For all tests, *P* values of <0.05 were considered statistically significant. The correlations between hepatic M-CoA content and hepatic TG as well as hepatic M-CoA content and hepatic collagen were analyzed using Pearson’s correlation coefficient.

**Results**

**Inhibition of Mouse ACC1 and ACC2.** The inhibitory activities of compound-1 and compound-2 (dual ACC1/2 inhibitor) (Kamata et al., 2012) on recombinant mouse ACC1 and ACC2 enzymes were evaluated. Compound-1 inhibited recombinant human ACC1 and ACC2 at IC$_{50}$ values of 0.58 nM and >10,000 nM, respectively (Mizojiri et al., 2018), as well as mouse ACC1 and ACC2 with IC$_{50}$ values of 1.9 nM and >10,000 nM, respectively (Table 1). Conversely, compound-2 inhibited mouse ACC1 and ACC2 with IC$_{50}$ values of 6.0 nM and 6.4 nM, respectively. These results indicate that compound-1 is selective for ACC1 inhibition, whereas compound-2 inhibits both ACC1 and ACC2.

**Effect of Compound-1 on M-CoA Content and DNL in HepG2 Cells.** To assess the effect of compound-1 on M-CoA content and DNL in cultured cells, we investigated the effect of compound-1 on M-CoA production and $[^{14}C]$ acetate incorporation into fatty acids in HepG2 cells. Compound-1 decreased the M-CoA content in cells with IC$_{50}$ of 16.0 nM (Fig. 1A) and inhibited $[^{14}C]$ acetate incorporation into fatty acids with IC$_{50}$ of 12.7 nM (Fig. 1B) in a dose-dependent manner. Additionally, the unbound fraction of compound-1 in the medium was 0.09. The estimated unbound compound-1–based IC$_{50}$ when compound-1 inhibited M-CoA production and $[^{14}C]$ acetate incorporation was 1.44 nM and 1.14 nM, respectively.

**Effect of Compound-1 on Hepatic M-CoA Content and DNL in C57BL/6J Mice.** M-CoA is formed from acetyl-CoA by ACC, and the hepatic M-CoA level could be used as a pharmacodynamic marker of ACC inhibition (Glien et al., 2011; Harriman et al., 2016). Therefore, we assessed the ability of compound-1 to suppress hepatic M-CoA content in C57BL/6J mice, which were fed normal chow. At 2 hours after a single dose, compound-1 significantly and dose-dependently decreased hepatic M-CoA content from the lowest tested dose of 0.3 mg/kg. The efficacy of compound-1 tended to plateau at approximately 30 mg/kg, and a maximum reduction of −64% was noted at 100 mg/kg (Fig. 2A). Conversely, compound-2 (100 mg/kg, to achieve >85% inhibition), an ACC1/2 dual inhibitor, reduced hepatic M-CoA by 88% compared with vehicle (Fig. 2A). To analyze the correlation between compound-1 blood exposure and hepatic M-CoA reduction, we measured the plasma concentration of compound-1 at 2 hours after dose. We already confirmed that the plasma and hepatic concentrations of compound-1 were similar in a separate time-course study. Thus, the plasma concentration can be used as the index for analyzing the pharmacokinetics and pharmacodynamics (unpublished data). The IC$_{50}$ of hepatic M-CoA reduction was 1.88 μg/ml (0.90 mg/kg) of plasma concentration in C57BL/6J mice (Supplemental Table 1). The exploratory in vitro study suggested high plasma protein binding of compound-1 to mice plasma, and the estimated unbound compound-1–based IC$_{50}$ was <5 nM. We also confirmed that compound-1 (10 mg/kg) did not change the M-CoA content in muscles in which ACC2 is predominantly expressed 1 hour after a single dose (unpublished data).

To assess DNL inhibition by compound-1 in vivo, we evaluated the inhibition of $[^{14}C]$ acetate incorporation into fatty acids in mice that were fed WD. Compound-1 (10 mg/kg) inhibited hepatic fatty acid synthesis in WD-fed C57BL/6J mice by 77.6% and 67.8% at 2 and 5 hours after oral administration, respectively (Fig. 2B).

Based on these pharmacodynamic results, we selected the doses of 3, 10, and 30 mg/kg for the repeated dose study to investigate the anti-NAFLD/anti-NASH effect of compound-1 in WD-fed MC4R KO mice.

**TABLE 1**

<table>
<thead>
<tr>
<th>Compound</th>
<th>mouse ACC1 IC$_{50}$ (nM)</th>
<th>mouse ACC2 IC$_{50}$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound-1</td>
<td>1.9</td>
<td>&gt;10,000</td>
</tr>
<tr>
<td>Compound-2</td>
<td>6.0</td>
<td>6.4</td>
</tr>
</tbody>
</table>

**Fig. 1.** Effect of compound-1 on M-CoA content and fatty acid synthesis in HepG2 cells. (A) Effect of compound-1 on M-CoA content in HepG2 cells. (B) Effect of compound-1 on $[^{14}C]$ acetate incorporation into fatty acids in HepG2 cells. Data are presented as the mean ± S.D. (*n* = 3).
Compound-1 Improves Hepatic Steatosis and Fibrosis in WD-Fed MC4R KO Mice. To evaluate the effects of compound-1 on NAFLD/NASH, we orally administered compound-1 to WD-fed MC4R KO mice once daily for 8 weeks at doses of 3, 10, and 30 mg/kg.

The liver weight and hepatic TG content in WD-fed MC4R KO mice were significantly higher than those in WT mice (Fig. 3, A and B). The total liver weights in compound-1–treated groups (3, 10, and 30 mg/kg) were reduced by 9.1%, 23.8%, and 57.1%, respectively, compared with that in the vehicle-treated group (Fig. 3A). Additionally, consistent with the improvement of the appearance of fatty liver (unpublished data), compound-1 significantly reduced the total hepatic TG at doses of 10 and 30 mg/kg (Fig. 3B). These results indicate that compound-1 improves liver hypertrophy and steatosis.

All animals in the compound-1–treated group (30 mg/kg) showed abnormal findings, such as dryness of the tail, loss of fur around the chest, and flushing of the face on day 56 (unpublished data). No other abnormalities were observed in terms of anatomy and appearance. Only at 30 mg/kg did compound-1 treatment significantly decrease BW without reducing the cumulative FI (Fig. 3, C and D); however, the BW reduction was not correlated with the severity of skin toxicity.

The plasma parameter levels were evaluated before and after the 8-week treatment of compound-1 (Table 2). At the start of drug treatment, plasma AST and ALT, which are hepatic enzymes that could be used as markers of hepatocellular injury (Zechini et al., 2004), and TC levels were higher in WD-fed MC4R KO mice than in WT mice. In contrast, plasma TG levels were lower in WD-fed MC4R KO mice than in WT mice. These data suggested that WD-fed MC4R KO mice exhibited hepatocellular injury and lipid metabolism disruption.

Compound-1 treatment markedly decreased plasma AST, ALT, and TC levels in a dose-dependent manner, whereas the treatment increased plasma TG concentrations compared with those in the vehicle-treated group. However, plasma TG levels in the compound-1–treated mice never reached statistically significant increased values over those observed in the WT mice.

The plasma concentration and pharmacokinetic parameters of compound-1 before and after the final dose are shown in Supplemental Table 2.

To evaluate the effects of compound-1 on markers of inflammation and fibrosis, we measured the mRNA expression of ACC1 and ACC2, which are hypothesized to be induced by hepatic steatosis, consistent with the findings of previous studies (Itoh et al., 2011; Konuma et al., 2015; Shiba et al., 2018). Compound-1 significantly decreased the gene expression levels of ACC1 and ACC2, in the liver. Compared with WT mice, WD-fed MC4R KO mice treated with vehicle showed remarkable elevation in the expression levels of MCP-1, F4/80, Col1a1, Col1a2, α-SMA, and TGF-β1 as markers of fibrosis activity in the liver. Additionally, we evaluated the expression of lipogenesis-related genes, including ACC1 and ACC2, in the liver. Consistent with these findings, compound-1 significantly decreased the gene expression levels of MCP-1, F4/80, Col1a1, Col1a2, α-SMA, and TGF-β1 (Fig. 4), suggesting progression to NASH with macrophage infiltration induced by MCP-1, which are hypothesized to be induced by hepatic steatosis, was observed in this mouse model. Additionally, we confirmed that the expression of ACC1, Fasn, and Scd1 was increased in this model (Supplemental Fig. 1); these are consistent with the findings of previous studies (Itoh et al., 2011; Konuma et al., 2015; Shiba et al., 2018). Compound-1 significantly decreased the gene expression levels of ACC1, ACC2, Fasn, and Scd1 in WD-fed MC4R KO mice. Compound-1 dose-dependently reduced hepatic M-CoA content, and the maximum efficacy was observed in the 30-mg/kg group, which was 62% lower than that in the vehicle-treated group (Fig. 5).

We measured the hepatic M-CoA content as a pharmacodynamic marker at 20 hours after the final dose in WD-fed MC4R KO mice. Compound-1 dose-dependently reduced hepatic M-CoA content, and the maximum efficacy was observed in the 30-mg/kg group, which was 62% lower than that in the vehicle-treated group (Fig. 5).

Additionally, we investigated the antifibrotic effect of compound-1 by conducting biochemical and histologic analyses in the liver. Hepatic collagen content and Sirius red–positive area were significantly higher in WD-fed MC4R KO mice than in WT mice (Fig. 6, A, B, and C). Compound-1 significantly decreased hepatic collagen (mg/liver) at doses of 10 and 30 mg/kg and Sirius red–positive area at doses of 3 and 10 mg/kg. Notably, hepatic M-CoA reduction was correlated with
the decrease in hepatic TG and collagen (Fig. 6, D and E; \( R^2 = 0.5716, \text{****}P < 0.0001, \) and \( R^2 = 0.5472, \text{****}P < 0.0001 \)).

**Discussion**

Hepatic DNL is markedly higher in patients with NAFLD than in healthy individuals (Donnelly et al., 2005; Fabbrini et al., 2008; Lambert et al., 2014), and ACC1—the rate-limiting enzyme for hepatic DNL—is upregulated in patients with NAFLD (Kohjima et al., 2007), which suggests that abnormal ACC1 activity contributes to the pathogenesis of fatty liver, a key feature of NAFLD. In the current study, compound-1, a novel selective ACC1 inhibitor, was found to influence hepatic

![Graphs showing the effects of compound-1 on liver weight, TG, BW change, and FI in WD-fed MC4R KO mice.](image)

Table 2: Effect of chronic compound-1 on plasma parameters in WD-fed MC4R KO mice

<table>
<thead>
<tr>
<th>Mice</th>
<th>Treatment</th>
<th>AST (IU/l) Pre</th>
<th>AST (IU/l) Post</th>
<th>ALT (IU/l) Pre</th>
<th>ALT (IU/l) Post</th>
<th>TG (mg/dl) Pre</th>
<th>TG (mg/dl) Post</th>
<th>T-Cho (mg/dl) Pre</th>
<th>T-Cho (mg/dl) Post</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>41.8 ± 7.0</td>
<td>636.9 ± 964</td>
<td>22.1 ± 4.6</td>
<td>857.6 ± 103.9</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>95.5 ± 6.2</td>
<td>405.5 ± 22.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64.3 ± 12.8</td>
<td>694.6 ± 86.7</td>
<td>857.6 ± 103.9</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>95.5 ± 6.2</td>
<td>405.5 ± 22.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.1 ± 4.6</td>
<td>857.6 ± 103.9</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.1 ± 4.6</td>
<td>857.6 ± 103.9</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.1 ± 4.6</td>
<td>857.6 ± 103.9</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22.1 ± 4.6</td>
<td>857.6 ± 103.9</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
<td>20.4 ± 14.1</td>
<td>840.7 ± 124.4</td>
</tr>
</tbody>
</table>

Plasma parameters were measured before (Pre) and after (Post) 8 weeks of treatment. Data are presented as the mean ± S.D. (n = 5–8). **P < 0.001 vs. vehicle-treated WT mice by Student’s t test; \(* P < 0.001 vs. vehicle-treated WT mice by Aspin-Welch test; **P < 0.01 and ***P < 0.001 vs. vehicle-treated WD-fed MC4R KO mice by Dunnett’s test; \(* P < 0.05 and ***P < 0.001 vs. vehicle-treated WD-fed MC4R KO mice by Steel’s test.**
M-CoA concentrations, which in turn reduced hepatic lipid accumulation and prevented hepatic fibrosis in WD-fed MC4R KO mice.

First, we determined that compound-1 is highly selective at the enzyme level for mouse ACC1 and not ACC2, thus providing a candidate molecule for further studies on the biological function of ACC1. We also confirmed the effect of compound-1 on the pharmacodynamic marker M-CoA in a liver cell model indicating that ACC1 inhibition is sufficient to reduce intracellular M-CoA concentrations. The cellular M-CoA production and subsequent fatty acid synthesis were dose-dependently suppressed by compound-1 treatment. Therefore, compound-1 inhibits M-CoA content and fatty acid synthesis in hepatocytes by selectively blocking ACC1 and could represent a potential therapeutic strategy for improving hepatic steatosis.

To confirm that the reduced in vitro DNL translates in vivo, we administered a selective ACC1 inhibitor to C57BL/6J mice. Hepatic M-CoA concentrations negatively correlated with the plasma concentration of compound-1 and fatty acid synthesis, which were measured by the incorporation of acetate into lipids, were significantly suppressed by compound-1 treatment (10 mg/kg; Fig. 2; Supplemental Table 1). Additionally, we confirmed the ACC1 selectivity for compound-1 in vivo by comparing its effect on the reduction in M-CoA levels in the liver and

---

Fig. 4. Effect of chronic compound-1 on hepatic mRNA expression in WD-fed MC4R KO mice. Gene expression of (A) MCP-1, (B) F4/80, (C) Col1a1, (D) Col1a2, (E) αSMA, and (F) TGF-β1. Data are presented as the mean ± S.D. (n = 5–8). *P < 0.05 and **P < 0.001 vs. WT by Student’s t test; $$$P < 0.001 vs. WT by Aspin-Welch test; *P < 0.05 vs. vehicle by Dunnett’s test; $P < 0.05$ and **P < 0.01 vs. vehicle by Steel’s test.

Fig. 5. Effect of chronic compound-1 on total hepatic M-CoA content in WD-fed MC4R KO mice. Data are presented as the mean ± S.D. (n = 5–8). ***P < 0.001 vs. vehicle by Dunnett’s test.
muscles. These results support that compound-1 inhibits DNL via ACC1 inhibition in vivo and corroborates the in vitro results.

We also evaluated the impact of ACC1 inhibition on steatosis and fibrosis through repeated compound-1 dosing in a genetic and diet-induced WD-fed MC4R KO mouse model. This model shows multiple histopathological features common to patients with NASH, including hepatic steatosis, inflammation, and fibrosis. Furthermore, the expression of liver lipogenesis-related genes, including ACC1, is elevated in this mouse model compared with WT control mice (Itoh et al., 2011; Konuma et al., 2015; Shiba et al., 2018). The reported pathological features in this model were also noted in our WD-fed MC4R KO mice. In contrast to the increased ACC1 expression, expression of ACC2 was unchanged in the livers of model mice compared with that in WT mice (Supplemental Fig. 1). This is consistent with the findings of a previous study on human patients with NAFLD (Kohjima et al., 2007), which suggests that ACC1 might contribute more strongly to NAFLD progression than ACC2.

After 8 weeks of compound-1 treatment, hepatic TG accumulation was attenuated and plasma AST and ALT levels were significantly reduced, indicating that ACC1 inhibition improved hepatic steatosis resulting in ameliorated hepatocellular damage. Furthermore, compound-1 reduced the mRNA expression of genes related to inflammation and collagen synthesis marker
levels, hepatic collagen content, and Sirius red–positive area, which suggests that ACC1 inhibition can also reduce inflammation and fibrosis progression either directly by its inhibition in nonhepatocytes or indirectly by reducing the hepatic lipid content (Bates et al., 2020). Indeed, we observed a correlation between reduced M-CoA concentration via ACC1 inhibition and reduced hepatic TG and collagen content. Cumulatively, these results suggest that inhibiting hepatic DNL by selective ACC1 inhibition may represent a viable strategy for treating NAFLD/NASH.

Although the Sirius red–positive area was not reduced after treatment with 30 mg/kg of compound-1, this may not be attributed to the diminished antiobesity efficacy but rather the remarkable improvement of liver hypertrophy, which increases the total analysis area per analysis unit screen at 30 mg/kg compared with that in the other groups. Indeed, fibrosis gene expression and total hepatic collagen content were dose-dependently decreased after compound-1 treatment. However, further studies are needed to address the discrepancy between the hepatic collagen content and Sirius red–positive area.

BW loss was observed in WD-fed MC4R KO mice treated with 30 mg/kg compound-1 compared with vehicle-treated mice. Although the improvement in hepatic hypertrophy could partially be considered a cause of the BW loss, we hypothesize that compound-dependent toxicities account for the primary cause at the highest dose. Heterozygous ACC1 mutant mice and liver-specific ACC1-deficient mice did not show BW reduction compared with WT mice (Abu-Elheiga et al., 2005; Harada et al., 2007), indicating that the inhibition of ACC1 in the liver is not responsible for the reduced BW. We further evaluated the specificity of compound-1 for 72 panels, including G-protein–coupled receptor, kinase, non–kinase enzyme, ion channel, transporter, and nuclear hormone receptor up to concentrations of 10 μM, and the compound corresponded to only 5-hydroxytryptamine receptor 2B (HTR2B) (IC50 = 3.3 μM; unpublished data). However, this efficacy of HTR2B is not expected to have contributed to the observed in vivo toxicity since the estimated unbound fraction-based Cmax at 30 mg/kg in WD-fed MC4R KO mice was <160 nM, which was >20-fold lower than the in vitro IC50 against HTR2B.

We were unable to discern the impact of weight loss observed with 30 mg/kg compound-1 on the improvement in NASH caused by ACC1 inhibition. Previously we confirmed that 15% calorie restriction resulted in 11.6% reduction in BW without significantly reducing plasma ALT and AST levels or hepatic collagen content in WD-fed MC4R KO mice compared with animals fed ad libitum (unpublished data). However, marked BW loss (>10%) improved fibrosis in patients with NAFLD/NASH (Mummadi et al., 2008, Glass et al., 2015). Therefore, further studies are needed to confirm whether BW loss or ACC1 inhibition was responsible for the anti-NASH effect of compound-1 at 30 mg/kg.

Many preclinical and clinical studies have shown that ACC1/2 dual inhibitors increase plasma TG concentrations, which may be a signaling cascade that upregulates TG reesterification genes and flux (Kim et al., 2017; Goedeke et al., 2018; Chen et al., 2019; Bergman et al., 2020; Matsumoto et al., 2020). Indeed, compound-1 significantly increased the expression of ACC1, Fasn, and Scd1, which are sterol regulatory element-binding protein 1c target genes. However, compound-1 did not significantly elevate plasma TG concentrations compared with WT mice (Table 2). We also confirmed that repeated compound-1 dosing for 8 weeks did not increase plasma TG levels in the amylin liver NASH diet-fed NASH model, a diet-induced preclinical NAFLD/NASH mouse model, compared with those in lean and vehicle-treated mice (unpublished data). Since serum TG concentrations are not increased by ACC1/2 inhibitors at a dose that partially inhibits hepatic DNL (Bergman et al., 2020), and since the cellular specific hepatic M-CoA level is compensated by ACC2 activity under ACC1 inhibition conditions (Mao et al., 2006; Harada et al., 2007), one possible explanation for this difference in plasma TG elevation between ACC1/2 inhibitors and a selective ACC1 inhibitor might be that the latter is unable to fully suppress hepatic M-CoA production because of the flux via ACC2. In our study, the maximum M-CoA–lowering effect by selective ACC1 inhibition was less than that by ACC1/2 inhibition. Additionally, hepatic ACC2 expression was dose-dependently induced by compound-1 after repeated dosing in WD-fed MC4R KO mice (Supplemental Fig. 1). Although further investigations are required, these data suggest that a selective ACC1 inhibitor could improve hepatic steatosis and fibrosis without causing plasma TG elevation because ACC2 compensates the hepatic M-CoA level under ACC1 inhibition, thereby preventing any secondary feedback, including increased circulating TGs.

In conclusion, to our knowledge, this is the first study to show that a selective ACC1 inhibitor has sufficient efficacy in preclinical models, thus providing a viable approach for treating NAFLD/NASH. The data demonstrate a robust reduction in hepatic steatosis and fibrosis in our preclinical animal models. Additionally, selective ACC1 inhibition mitigates the increased TG concentrations observed with ACC1/2 inhibitors in clinical studies. These findings support the ACC1 inhibitor as a potential novel treatment of NAFLD/NASH.

Acknowledgments
The authors are grateful to Nobuyuki Amano, Yuichihiro Amano, Ryo Mizojiri, and Noboru Tsuchimori from the Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, and Noriko Uchiyama from Global Drug Safety Research Division, Takeda Pharmaceutical Company Limited, Cambridge, MA, for their guidance and valuable comments. The authors would like to acknowledge all Takeda ACC1 project members, especially Kazue Tsuchimori and Sayaka Nakagawa from the Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.

Authorship Contributions
Participated in research design: Tamura, Sugama, Iwasaki, Sasaki, Yasuno, Aoyama, Watanabe, Erion, Yashiro.
Conducted experiments: Tamura, Sugama, Iwasaki, Sasaki, Yasuno, Aoyama, Yashiro.
Performed data analysis: Tamura, Sugama, Iwasaki, Sasaki, Yasuno, Aoyama, Yashiro.
Wrote or contributed to the writing of the manuscript: Tamura, Sugama, Iwasaki, Yasuno, Aoyama, Watanabe, Erion, Yashiro.

References


Lambert JE, Ramos-Roman MA, Browning JD, and Parks EJ (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology* 146:726–735.


**Address correspondence to:** Hiroaki Yashiro, Gastroenterology Drug Discovery Unit, Takeda Pharmaceuticals International Co., 350 Massachusetts Ave., Cambridge, MA 02139. E-mail: hiroaki.yashiro@takeda.com
Supplementary Materials and Methods

Measurement of pharmacokinetics in mice

Plasma concentrations of compound-1 were measured using the LC/MS/MS method. Plasma was precipitated using acetonitrile containing the internal standard, diclofenac. The precipitated sample was centrifuged for 5 min at approximately 3000 × g. The supernatants were diluted with the mobile phase and injected into the LC/MS/MS system. This system comprised a 20AD-VP system (Shimadzu, Kyoto, Japan) and a triple quadrupole mass spectrometry detection API-5000 (AB Sciex, Framingham, MA, USA), equipped with a turbo ion spray ionization source in the positive ionization mode. Chromatographic separation was achieved using a reversed phase (C18) column [Shim-pack XR-ODS (2.2 μm, 2.0 × 30 mm); Shimadzu, Kyoto, Japan] at 50 °C. The mobile phase consisted of 0.2% (v/v) formic acid in 0.01 M ammonium formate (pH 3.0; solvent A) and 0.2% (v/v) formic acid in acetonitrile (solvent B), which was delivered at a flow rate of 0.7 mL/min. The analyte was eluted using a linear gradient of 95% solvent A/5% solvent B to 5% solvent A/95% solvent B. Detection was performed using multiple reaction monitoring in the positive ionization mode (SRM m/z = 424.2 → 101.1 for T-3773082 and m/z = 296.1 → 214.2 for diclofenac). Analyst software™ (version 1.6.2; AB Sciex) was used for data acquisition and processing. The concentration of compounds in each sample was back calculated using a calibration curve generated from a set of calibration standards.
Supplementary data

Supplementary Table S1. Plasma compound-1 concentration in normal-fed C57BL/6J mice 2 h after oral administration

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Plasma concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>0.3</td>
<td>0.686</td>
</tr>
<tr>
<td>1</td>
<td>2.243</td>
</tr>
<tr>
<td>3</td>
<td>6.045</td>
</tr>
<tr>
<td>10</td>
<td>18.762</td>
</tr>
<tr>
<td>30</td>
<td>51.018</td>
</tr>
<tr>
<td>100</td>
<td>115.174</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± SD (n = 5)
Supplementary Table S2. Plasma concentration and pharmacokinetic parameters of compound-1 in the plasma of WD-fed MC4R KO mice after 8 weeks of repeated oral administration

(A)  
<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Plasma concentration (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
</tr>
<tr>
<td>0</td>
<td>2.138</td>
</tr>
<tr>
<td>0.5</td>
<td>6.699</td>
</tr>
<tr>
<td>1</td>
<td>8.427</td>
</tr>
<tr>
<td>2</td>
<td>8.239</td>
</tr>
<tr>
<td>6</td>
<td>5.679</td>
</tr>
</tbody>
</table>

(B)  
<table>
<thead>
<tr>
<th>Dose</th>
<th>3 mg/kg</th>
<th>10 mg/kg</th>
<th>30 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (μg/mL)</td>
<td>8.427</td>
<td>25.918</td>
<td>66.524</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>1.00</td>
<td>2.00</td>
<td>2.00</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-6h&lt;/sub&gt; (μg·h/mL)</td>
<td>42.160</td>
<td>134.320</td>
<td>345.404</td>
</tr>
<tr>
<td>MRT (h)</td>
<td>2.78</td>
<td>2.91</td>
<td>3.19</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± SD (n = 3).
Supplementary Figure S1. Effect of chronic compound-1 on hepatic mRNA expression in WD-fed MC4R KO mice. Gene expression of (A) ACC1, (B) ACC2, (C) Fasn, and (D) Scd1. Data are presented as the mean ± SD (n = 5–8). ***p < 0.001 vs. WT by Student’s t-test; SSS p < 0.001 vs. WT by Aspin–Welch test; ⁋ p < 0.05, ⁋ ⁋ p < 0.01 vs. vehicle by Steel’s test.